Efficacy and effectiveness of acellular pertussis vaccines: a 20-year Swedish experience

Hallander, Hans O.; Gustafsson, Lennart

doi:10.1586/erv.09.88

Cited by 23 publications

(9 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Of particular concern is the low coverage rate for Per for schoolchildren, despite the change from whole-cell Raising Per catch-up vaccination in this age group should be a priority, as adolescents and especially adults have long been recognized as a source of Bordetella pertussis transmission in young, unprotected infants, in addition to the problems of waning immunity over time and vaccine efficacy lower than the desired coverage needed for herd immunity. [19][20][21][22] As with measles, because of the suboptimal coverage level, circulation of the pathogen is unavoidable and can have tragic consequences, as in the case of the 2-year-old in one canton who died from a Per infection in 2009, the first mortality case in 10 years. 23 Although not presented in this article, there was a general increase in coverage at the canton level, with only two cantons exhibiting a possible decrease for all eight targeted antigens for toddlers; one canton for 8-year-olds for all except Per and Hib vaccines; and one canton for teenagers for Di, Te, and Pol vaccines.…”

Section: -17mentioning

confidence: 99%

The Swiss National Vaccination Coverage Survey, 2005–2007

et al. 2011

View full text Add to dashboard Cite

Objectives. We described the results from the Swiss National Vaccination Coverage Survey (SNVCS) [2005][2006][2007], a survey designed to monitor immunization coverage of children and adolescents residing in Switzerland in each canton within a three-year period.Methods. The SNVCS is a cross-sectional survey using a two-stage sampling design targeting children aged 2, 8, and 16 years. Families of selected children were contacted by mail and telephone. Coverage was determined via vaccination cards or vaccination summary forms.Results. A total of 25 out of 26 cantons participated in the survey, with 8,286 respondents for children aged 24-35 months, 10,314 respondents for children aged 8 years, and 9,301 respondents for teenagers aged 16 years. Compared with data from 1999-2003, coverage estimates for toddlers remained unchanged for diphtheria, tetanus, pertussis, poliomyelitis, and Haemophilus influenzae type b vaccines at three doses, but increased five percentage points to 86%-87% for measles-mumps-rubella at one dose and was 71% at two doses. Coverage for measles, mumps, and rubella were 89%-90% at one dose and 75% at two doses for 8-year-olds, and 94% and 76% for the two dosages, respectively, for 16-year-olds. Linguistic region and nationality were highly correlated with being vaccinated against measles for the two younger age groups.Conclusion. Despite the increase in vaccine coverage, measles vaccination is still low, and the World Health Organization goal to eliminate measles by 2010 was not achieved in Switzerland. More efforts are needed by the cantons and the central government to increase vaccination coverage.

show abstract

Section: -17mentioning

confidence: 99%

The Swiss National Vaccination Coverage Survey, 2005–2007

et al. 2011

View full text Add to dashboard Cite

show abstract

“…Whole-cell vaccine had been shown to have unacceptably high reactogenicity when given as a booster after a whole-cell primary course. Relative efficacy trials of highly purified acellular vaccines and whole-cell vaccines were under way in Sweden by the early 1990s [53,54]. The potential role of acellular pertussis (aP) vaccines for boosting was recognised at that time.…”

Section: Introduction Of An Acellular Booster Dosementioning

confidence: 99%

Pertussis immunisation and control in England and Wales, 1957 to 2012: a historical review

2013

View full text Add to dashboard Cite

This review summarises the epidemiology and control of pertussis in England and Wales since the introduction of routine immunisation and considers the implications for future control. Routine infant immunisation with a whole-cell pertussis (wP) vaccine was introduced in 1957 and had a marked impact on the overall disease burden. Following a fall in vaccine coverage during the 1970s and 80s linked to a safety scare with wP vaccine, there was an extended period of high coverage and pertussis incidence fell dramatically. Incidence continued to decrease with the introduction of an acellular pertussis vaccine in the preschool booster in November 2001 and in the primary United Kingdom (UK) schedule in September 2004 but has increased since July 2011. In response to a high rate of pertussis in infants, a temporary vaccination programme for pregnant women was introduced in October 2012. The key aim of the programme is to protect vulnerable infants from birth in the first months of life, before they can be fully protected by routine infant immunisation. A review of the UK adolescent immunisation programme is currently ongoing and the inclusion of a pertussis booster is being considered.

show abstract

“…Regarding the Danish PT toxoid vaccine (Di-Te-Kik), it was used exclusively in the Gothenburg region of Sweden from 1996 until the spring of 1999. The rate of pertussis (in children born between January 1996 and June 1999) between October 1997 and September 2004 was determined for children in the Gothenburg region and the rest of Sweden [1, 8]. The rate of pertussis (mostly vaccine failures) in the Gothenburg region was significantly higher in all children less than 8 years than the rate in the rest of Sweden, where a three component DTaP vaccine was predominantly used.…”

Section: Discussionmentioning

confidence: 99%

Evidence of Bordetella pertussis infection in vaccinated 1-year-old Danish children

et al. 2010

View full text Add to dashboard Cite

We measured IgA and IgG antibodies to pertussis toxin (PT) and filamentous hemagglutinin (FHA) in sera from 203 1-year-old children who had received one to three doses of a monocomponent PT toxoid vaccine. Ten children (5%) had IgA antibody to PT indicating recent infection; seven of these children had received three doses of vaccine. PT IgA responders did not have significantly longer coughing episodes than PT IgA non-responders. Since an IgA antibody response occurs in only ∼50% of infected children, the actual infection rate in our cohort is estimated to ∼10%. The apparent high Bordetella pertussis infection rate in Danish infants suggests that the monocomponent PT toxoid vaccine used in Denmark has limited efficacy against B. pertussis infection. A prospective immunization study comparing a multi-component vaccine with the present monocomponent PT toxoid vaccine should be undertaken.

show abstract

Efficacy and effectiveness of acellular pertussis vaccines: a 20-year Swedish experience

Cited by 23 publications

References 16 publications

The Swiss National Vaccination Coverage Survey, 2005–2007

The Swiss National Vaccination Coverage Survey, 2005–2007

Pertussis immunisation and control in England and Wales, 1957 to 2012: a historical review

Evidence of Bordetella pertussis infection in vaccinated 1-year-old Danish children

Contact Info

Product

Resources

About